key: cord-0456276-cjl2jjhm
authors: Lambert, Joshua; Sandhu, Harpal; Kean, Emily; Xavier, Teenu; Brokman, Aviv; Steckler, Zachary; Park, Lee; Stromberg, Arnold
title: A strategy to identify event specific hospitalizations in large health claims database
date: 2021-10-25
journal: nan
DOI: nan
sha: c9038ff61fbdac19ff31e5976dd51753523a5c3c
doc_id: 456276
cord_uid: cjl2jjhm

Health insurance claims data offer a unique opportunity to study disease distribution on a large scale. Challenges arise in the process of accurately analyzing these raw data. One important challenge to overcome is the accurate classification of study outcomes. For example, using claims data, there is no clear way of classifying hospitalizations due to a specific event. This is because of the inherent disjointedness and lack of context that typically come with raw claims data. In this paper, we propose a framework for classifying hospitalizations due to a specific event. We then test this framework in a health insurance claims database with approximately 4 million US adults who tested positive with COVID-19 between March and December 2020. Our claims specific COVID-19 related hospitalizations proportion is then compared to nationally reported rates from the Centers for Disease Control by age and sex.

Prescription and health insurance claims providers can deliver unique patient-level retail pharmacy, diagnosis, and procedure data. These data can range in size and complexity depending on the provider (1) (2) (3) . Successfully using these data in medical research is not an easy task and requires some key considerations (1) . Some of this difficulty comes from the lack of structure and context to how certain ICD-10, current procedural terminology (CPT), or drug codes are grouped with one another around an event of interest. For example, a hospitalization CPT code does not link to the diagnosis code that caused it, nor does the drug code that was prescribed because of the event. This disjointness is a major hurdle for researchers hoping to harness these large claims data for their research question of interest.

This issue arose in our own research, where we sought to use a large healthcare claims database. Like many others, Symphony Health Solutions provides its users with the data it gets from retail pharmacies, and medical claims. We then sought to use these data to reconstruct whether a patient who tested positive for COVID-19 was admitted to the hospital because of that diagnosis. We found that researchers like us (using Symphony Health Data), overcame this hurdle in a variety of ways.

To uncover how researchers deal with this lack of structure in claims data, a comprehensive literature search was conducted by a health sciences librarian (E. K.). EBSCOhost Academic Search Complete, Business Source Complete, CINAHL Plus with Full Text, MEDLINE with Full Text, and OmniFile Full Text Mega (H.W. Wilson) were searched from the dates of inception through August 2021. Additionally, the search consisted of a combination of keywords and equivalent subject headings representing "Symphony Health Solutions" as a company or a reference to the use of Symphony data. The results from the Symphony search were combined with a broad variety of terms representing the concepts of classification or categorization. An English language limit was applied to results, and after deduplication, 52 articles were retrieved.

Of the 52 articles retrieved, 32 articles were deemed relevant for this study. Of the 32 remaining articles, a clear pattern was identified as to how the authors chose to reconstruct the events of interest. Eighteen studies analyzed Symphony data using one timeline (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) to reconstruct the event. For example, Hampp et al. (7) used the Symphony Health Solutions PHAST Prescription Monthly database to investigate the antidiabetic drug use in the US population during a predefined single timeline. Six studies looked at data with one timeline but multiple follow-ups within a time range (22) (23) (24) (25) (26) (27) . Multiple timelines were used by eight of the retrieved papers (2, (28) (29) (30) (31) (32) (33) (34) . For example, Brixner et al. (2) conducted a longitudinal study using patient-level Symphony Health Solutions administrative claims data to assess the effectiveness of the HUMIRA Complete PSP in patients receiving adalimumab (ADA) treatment for broad range of diagnoses. They required the patients to have >2 claims which were at least 30 days apart to be included in the study.

Using this past work, as well as our own personal experience with claims data, we developed a generic methodology to reconstruct event specific hospitalizations. This proposed methodology is meant to act as a guide for how researchers can utilize health claims data in a more rigorous way.

Our event reconstruction strategy centers on the overlap of various event horizons (timelines) of interests. Specifically, when it comes to identifying event specific hospitalizations, the hospitalization event horizon is an important one to define. In Figure 1 , the hospitalization horizon is defined as Hto H + where each endpoint is an integer (ℤ). Event specific hospitalizations, by definition, must have the event of interest occur within the hospitalization is known about the unique patients within the dataset. Patient level CPT, diagnosis, and prescription codes were available from late 2018 to mid-2021. Using these data, which are contained in different tables accessible via the snowflake SQL platform, we utilized our event reconstruction strategy where we intended to reconstruct which, of the 4 million patients who tested positive for COVID-19, were hospitalized due to the COVID-19 diagnosis.

Using our generic definition, defined above, and outlined in Figure 1 , our clinical and research team decided the necessary event horizons endpoints. First, the hospitalization CPT code (99221, 99222, or 99223) needed to occur in the -2 to 14-day timeline from COVID diagnosis (U07.1). This time lag and lead were determined as claims do not always mimic the actual timeline that the patient experienced. A sensitivity analysis of these endpoints showed that most of the diagnoses and hospitalizations that met our -2 to +14 criteria actually occurred very close (-1 to +1) to one another. If multiple hospitalization CPT codes or multiple COVID-19 diagnoses codes occurred for a specific patient, then the minimum distance between all possible combinations of diagnoses and hospitalizations were considered. As a tie breaker the earliest minimum combination which met our criteria was considered as the COVID-19 hospitalization for that specific patient. If one of the combinations met the criteria of -2 to +14 then the patient was said to have met the first part of the criteria for being classified as diagnosis, 2 days before they were hospitalized, and had one of the other additional diagnoses 3 days after the hospitalization then that patient would be defined as a patient who was hospitalized due to a COVID-19 diagnosis.

The CDC provides estimates(35) of the number of symptomatic COVID-19 illness and the aggregate number of hospitalizations from February 2020 through May 2021. Unfortunately, we were unable to attain estimates for the same time period under investigation in our study (March 1 st , 2020, through December 31 st , 2020). Our methodology was developed independently of the CDC data, and the CDC data is meant to provide a type of external validation to our methodology. Table 1 provides a comparison of how our methodology on the Symphony data compares to the CDC's population estimates. Using the proposed methodology on the Symphony data, 2.7% of the patients in the age group of 18-49 years old were hospitalized due to a COVID-19 diagnosis.

The CDC's estimated that 3% of 18-49 years old were hospitalized due to symptomatic COVID-19. In the age group of 50-64 years old, 8.2% of the Symphony patients were hospitalized as compared to the 9.2% estimated by the CDC. In the age group of 65+ years old, 14.6% of the Symphony patients were hospitalized as compared to the 28.1% estimated by the CDC. Across all age groups the total percentage of Symphony patients hospitalized due to COVID-19 was 7.3% which is similar to the estimate of 7.5% by the CDC.

The difference observed in the 65+ population is worrisome and warrants serious attention.

Upon reinvestigation these results were not surprising as our Symphony data are from private insurance claims data and their estimates would be for those United States adults who were privately insured. In the United States, those who are 65+ years old qualify for Medicare and may not be privately insured. One explanation as to why so few 65+ in the Symphony data are not hospitalized due to a COVID-19 diagnoses (as compared to the CDC's estimates) is that they may be wealthier (can afford private insurance) and are therefore healthier on average. Table 1 While our sample is older on average than the general population, our methodology's overall estimates for the percent of COVID-19 diagnoses who were hospitalized due to a COVID-19

diagnosis is close to the CDC's overall estimates (7.3% vs. 7.5%). The main place to compare our methodology to the CDC estimates is in the portion of the US adult population who is likely privately insured (18-64 years). Within this group, our methodology seems to capture a percent of the sample similar to that of the CDC estimates.

A strength is that the methodology is a rigorous way to define cases in claims data based on multiple time horizons. In addition, this methodology can be used for other diseases events as well as other claims databases. Our attempt to validate this methodology vs the CDC's estimates showed similar estimates within those likely to be privately insured . The Symphony data has a high coverage rate: 92% of retail pharmacy claims, 71% of mail-order pharmacy claims, and 65% of specialty pharmacy claims, according to COVID-19 Research

Database (36) . No method is without its fair share of real limitations and considerations. First, no methodology will be able to take raw claims and produce results free from disputes as there will always be a lack of context and structure. Defining the time horizons is difficult, as there is likely great differences

Key considerations when using health insurance claims data in advanced data analyses: an experience report. Health Syst (Basingstoke)

Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug Spending

Adjusting Medicare capitation payments using prior hospitalization data. Health Care Financ Rev

Quantification of economic impact of drug wastage in oral oncology medications: comparison of 3 methods using palbociclib and ribociclib in advanced or metastatic breast cancer

Pre-exposure prophylaxis for preventing acquisition of HIV: A cross-sectional study of patients, prescribers, uptake, and spending in the United States

Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection

Use of antidiabetic drugs in the

Proprotein convertase subtilisin/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients

Diabetes Mellitus in Living Pancreas Donors: Use of Integrated National Registry and Pharmacy Claims Data to Characterize Donation-Related Health Outcomes

Occurrence of clinically diagnosed hypertrophic cardiomyopathy in the united states

Current and future projections of amyotrophic lateral sclerosis in the united states using administrative claims data

Effects of repository corticotropin injection on medication use in patients with rheumatologic conditions: A claims data study

Infusion administration billing for vedolizumab and infliximab in inflammatory bowel disease

Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection

Survival implications of opioid use before and after liver transplantation

Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome

Underuse of methotrexate in the treatment of rheumatoid arthritis: A national analysis of prescribing practices in the US

State naloxone access laws are associated with an increase in the number of naloxone prescriptions dispensed in retail pharmacies

The effects of a sitagliptin formulary restriction program on diabetes medication use. Am Health Drug Benefits

Pgi4 retrospective study of dose escalation with adalimumab, infliximab, and vedolizumab in the treatment of inflammatory bowel disease. Value Health

Clinical course of patients with worsening heart failure with reduced ejection fraction

Baseline characteristics and treatment patterns of patients with schizophrenia initiated on onceevery-three-months paliperidone palmitate in a real-world setting

Comparing Healthcare Costs Associated with Oral and Subcutaneous Methotrexate or Biologic Therapy for Rheumatoid Arthritis in the United States. Am Health Drug Benefits

Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib

Predicting medication persistence to buprenorphine transdermal system

Difference in Medication Adherence Between Patients Prescribed a 30-Day Versus 90-Day Supply After Acute Myocardial Infarction

Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study

Predonation prescription opioid use: A novel risk factor for readmission after living kidney donation

Model estimates of the burden of outpatient visits attributable to influenza in the United States

Impact of Early Initiation of Eslicarbazepine Acetate on Economic Outcomes Among Patients with Focal Seizure: Results from Retrospective Database Analyses

Prevalence of Hepatic Encephalopathy from a Commercial Medical Claims Database in the United States

Real-world incidence and cost of pneumonitis post-chemoradiotherapy for Stage III non-small-cell lung cancer

Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis. Rheumatol Ther

Homepage -COVID-19 Research Database